924 related articles for article (PubMed ID: 15986066)
1. Humoral and cellular immune response after measles vaccination in Taiwan.
Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
[TBL] [Abstract][Full Text] [Related]
2. Predicting and comparing long-term measles antibody profiles of different immunization policies.
Lee MS; Nokes DJ
Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
[TBL] [Abstract][Full Text] [Related]
3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
4. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
[TBL] [Abstract][Full Text] [Related]
5. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
[TBL] [Abstract][Full Text] [Related]
8. Rubella seroprevalence among young women taipei county after routine measles, mumps and rubella immunization program.
Wang IJ; Hwang KC; Tsai YH; Wu YN; Chao SJ; Chen TE; Huang LM
Acta Paediatr Taiwan; 2006; 47(1):14-7. PubMed ID: 17016964
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
10. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
Yekta Z; Pourali R; Taravati MR; Shahabi S; Salary S; Khalily F; Farzin A
East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767
[TBL] [Abstract][Full Text] [Related]
11. Sustained measles elimination in Australia and priorities for long term maintenance.
Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
[TBL] [Abstract][Full Text] [Related]
12. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
Belaunzarán-Zamudio PF; García-León ML; Wong-Chew RM; Villasís-Keever A; Cuellar-Rodríguez J; Mosqueda-Gómez JL; Muñoz-Trejo T; Escobedo K; Santos JI; Ruiz-Palacios GM; Sierra-Madero JG
Vaccine; 2009 Nov; 27(50):7059-64. PubMed ID: 19799846
[TBL] [Abstract][Full Text] [Related]
13. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
15. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
[TBL] [Abstract][Full Text] [Related]
17. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination.
Jokinen S; Osterlund P; Julkunen I; Davidkin I
J Infect Dis; 2007 Sep; 196(6):861-7. PubMed ID: 17703416
[TBL] [Abstract][Full Text] [Related]
18. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.
Kelly HA; Gidding HF; Karapanagiotidis T; Leydon JA; Riddell MA
BMC Public Health; 2007 Jun; 7():99. PubMed ID: 17555601
[TBL] [Abstract][Full Text] [Related]
19. National serologic survey of measles immunity among persons 6 years of age or older, 1988-1994.
Hutchins SS; Redd SC; Schrag S; Kruszon-Moran D; Wooten K; McQuillan GM; Bellini W; Meyer PA; Hadler S
MedGenMed; 2001 Jan; ():E5. PubMed ID: 11320344
[TBL] [Abstract][Full Text] [Related]
20. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
